

Different Features of the Regulatory T Cells in Gastrointestinal Tract Cancers and Disorders

Marziye Norozian, Abbas Ghaderi*

Shiraz Institute for Cancer research, Shiraz University of Medical Sciences, Shiraz Iran.

*Corresponding address. Prof A .Ghaderi, Shiraz Institute for Cancer Research, Shiraz Iran.

Tel.+98-711 2303687

Email: ghaderia@sums.ac.ir.

Received: Feb 4, 2016; Revised: Apr 5, 2016; Accepted: Apr 26, 2016

Introduction: Regulatory T cells (Treg) located in tissues have a critical role in controlling homeostasis and immune responses also modulate non-immunological processes. The T cell receptor repertoires of non-lymphoid tissue Tregs are distinct from Tregs in lymphoid organs. Less information is available about various ways to change the program of transcription in tissue-resident subsets of Treg cells for adapting to very different fields. However, recent progress in our understanding of Treg cells that reside in two important sites, the gut and adipose tissue, may provide some clues. Gastrointestinal is the largest reservoir for tissue-resident Treg cells in the body. Adequate number and performance of intestinal Treg cells are essential for maintaining normal intestinal immune homeostasis. Regulatory T cells in the GI tract have shown conflicting features. Therefore, in this study, phenotypic and functional characteristics of Treg cells are discussed in normal conditions, chronic inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as Treg cell therapeutic strategies in the treatment of these diseases.

Keywords: Regulatory T cells (Treg), inflammatory bowel disease (IBD).

Introduction

Regulatory T cells are involved in the immune system that plays an important role in various cancers, autoimmune diseases and infectious diseases. (1, 2) These cells can be formed in the thymus followed by self antigen identification, in the gut followed by interaction with antigen-specific cell subsets or in vitro in response to cytokines such as TGF- β . Two main subsets of CD4⁺ regulatory T cells (Treg) include: thymus-derived *natural regulatory T cells* (tTreg or nTreg) with suppression activities which are essential for establishing and maintaining immune homeostasis in steady state; *induced Treg cells* (iTreg) that arise from naive T cells followed by self antigen identification outside of the thymus, such as interleukin-10 (IL-10)-secreting T regulatory type 1 (Tr1) cells that do not express Foxp3 and CD25 markers or at the very least, Th3 cells that secrete high level of TGF- β which they express CD25 and FOXP3 markers and IL-35-secreting iTreg cells that do not express FOXP3 (3-5).

Other lymphocyte subsets with regulatory function include: inducible CD8⁺, CD3⁺CD4⁻CD8⁻ Treg, CD4⁺V α 14⁺ (NKTreg) and $\gamma\delta$ T cells. FOXP3 is considered as a key transcription factor controlling evolution and function of T regulatory cell. (6) However, in human, expression of Foxp3 alone is not sufficient to identify Treg

cells. Besides subsets of cells T CD4 + CD25^{hi}, FOXP3 is expressed by some of T CD4 + cells with low levels of CD25 or without CD25. FOXP3 expression may be induced in human T cells that are without Treg function (7).

Treg cells migrate to inflammatory site and draining lymph nodes during the immune response for suppressive action. These mechanisms include inhibitory cytokine production such as IL-10, TGF- β and IL-35; inducing functional cell death by taking and completing the cytokines such as IL-2 or production of granzyme B, creating localized metabolic disorder in target cells; and ultimately inhibition of dendritic cell function (8).

Immune responses in various tissues are affected by Treg FOXP3 + cells. For example, in the intestine, Treg cells have a key role in maintaining tissue homeostasis by inhibiting excessive activation of DC cells and effector T cells. Treg cells modulate the response to commensal microbes in the lamina propria tissue (9). Treg cells have been shown that similarly to autoimmunity in the central nervous system (CNS) can have beneficial effects by inhibiting (or shortening the bindings) inflammatory loop of T cells and APCs (10). Such a mechanism could have the opposite results in tumor that the Treg cells can inhibit the immune response against the tumor, preventing tumor clearance. Treg cells

maintain a delicate balance in the course of infection; inhibition of immune response leads to the inability to pathogen clearance, while uncontrolled immune response results in tissue destruction by unwanted immune response. Under special circumstances, in FOXP3+ Tregs can occur loss of Foxp3 expression and suppression functions(11). The key causes of this loss of FOXP3 expression include inflammatory environments with high levels of cytokines that are involved in the induction of effector T cells, such as IL-6 and IFN- γ (12).

Regulatory T cells in gastrointestinal (GI)

Treg cells in addition to peripheral blood and secondary lymphoid tissues can also be found in non-lymphoid tissues such as the skin, lung, liver, intestine, adipose tissue and placenta in non-inflammatory conditions(13). Overall, the analysis of Treg cells in these tissues has shown the characteristics of programmed effector Treg cell along with other detection features such as specific combinations of molecules implantation, transcription factors, mechanisms of immunoregulatory and TCR pool, indicating considerable expertise of Treg cells in these environments. Colonic Tregs are an unusual population, which has provoked some contradictory observations. TCRs expressed by colonic Treg cells show clear reactions against microbial antigens, which seems to be important triggers for proliferation and differentiation of these cells(14, 15). Accordingly, many studies have demonstrated a reduction in the frequency of colonic Treg cells in germ-free mice and colonization of GF mice by a group of clostridium bacteria leads to differentiation or proliferation of colonic Treg cells (16, 17).

Treg induction in the intestinal mucosa:

Abundant iTreg cells are in the intestine, but not in the secondary lymphoid tissues, and this reminds that iTreg cells evolve in response to intestinal antigens derived from commensal bacteria or food(18). Now, it is clear that the development of Treg cells outside the thymus occurs in the gut. In germ-free mice have been shown that in normal circumstances, the small intestinal iTreg cells are induced by food antigens and whereas colonic iTregs are induced by commensal bacteria (19, 20).

Intestinal dendritic cells can induce antigen-specific Treg cells, which are mainly involved in controlling the immune response against the dietary antigens and commensal microbes. Retinoic acid (RA) is a major factor in the induction of Treg as well as homing tendency of activated cells in the mucosa; also RA is not able to induce alone the expression of FOXP3, but upregulate expression in combination with TGF- β (21). RA, mediating orientation of Treg cells to the gut, is a strong induction for CCR9 and $\alpha 4\beta 7$ expression(22).

Induced Treg cells produced by CD103+ dendritic cells and stromal cells specific to the mesenteric

lymph nodes have a key role in inducing and maintaining oral tolerance(23). Several subsets of Treg cells such as, CD4+ FOXP3+ iTreg cells, IL-10-producing Tr1 cells and TGF- β -producing Th3 cells have been shown in oral tolerance(24).

Among subsets of Tregs, the role of FOXP3 Treg cells (nTregs and iTregs) in oral tolerance is the best studied. Inhibition of differentiation of iTreg by preventing the induction of TGF- β -dependent FOXP3 showed that iTreg cells are essential to inhibit the Th2 type diseases in mucosal sites (25). In addition, the lack of iTreg cells alters the composition of the intestinal microbiota. Therefore, this study suggests that tTreg cells are primarily responsible for the control of autoimmune response, whereas the main role of iTreg cells would be to prevent immune responses against commensal and dietary antigens. This idea is further supported by another study analyzing the TCR repertoire of colonic Treg cells. The comparison of the TCR repertoire of Tregs from this site with other locations revealed that gut antigens form the Treg TCR repertoire in the intestine(26). In fact, a large proportion of colonic Treg cells are specific for bacterial antigens, indicating that iTregs compose a major proportion of the gut Treg cells. However, another recent research showed that the TCR repertoires of intestinal and thymic Treg cells are highly similar, suggesting that tTreg cells also contribute significantly to the intestinal Treg pool(14). Therefore, both iTregs and tTreg cells are likely to contribute to the maintenance of intestinal homeostasis, and it remains to be cleared which population plays an important role. The cells of iTreg and nTreg have synergistic function because of having different TCR repertoire without redundancy(27). Both iTregs and nTregs express CD25 and the key Treg lineage transcription factor, so the distinction between these two populations in the peripheral organs remains challenging. Now, Helios and Nrp-1 are two proposed markers for this discrimination. However, these markers are not adequate as diagnostic markers of Treg subsets. Transcription factor Helios has been shown to be expressed at higher level on tTreg cells that can detect them from iTregs(28). But, previous researches have demonstrated that Helios could also be expressed by iTreg cells in vivo (29). In addition, a part of human tTreg cells do not express Helios (30). Nrp-1 is expressed by tTreg cells and lack of its expression in iTreg cells gives distinction between these two populations under non-inflammatory conditions(31). However, the expression of Nrp-1 may be induced in activated effector T cells in humans(32). Therefore, the lack of clear markers has caused to be limited our understanding of the relative contribution of tTreg and iTreg cells in pathology, especially in humans.

Controlling the intestinal regulatory T-cells homeostasis by dietary antigens and commensal microbes

The intestinal mucosa is constantly exposed to a various range of foreign antigens, such as dietary antigens, metabolites, and components of the commensal microbiota(33).

The presence of distinct microbial species increases specialized host immune responses by differentiation of appropriate Treg and effector T cells. Colonization with segmented filamentous bacteria (SFB) leads to effector T cells accumulation within the small intestine, especially Th17, and to a lower degree Th1 cells (34). Also, populations of regulatory T-cell are affected by microbial colonization that can result in accumulation of FOXP3⁺ Treg cells populations and induction of IL-10 production. Experiments using germ-free mice have shown that commensal bacteria are essential for the evolution of normal colonic Treg cells. Studies indicated that *Bacteroides fragilis* and clostridia species are important for intestinal regulatory T-cells homeostasis(19, 35). The most recently, 17 clostridial species were identified in the human microbiota, which induce gut-homing and proliferation of Treg cells. In addition, it was found that these 17 species provide a relatively high level of short chain fatty acids (SCFAs) that are the products of bacterial decomposition from plant fiber(36). It was shown that the SCFA such as propionate, butyrate and acetate are able to restore the number of Treg cells in mice treated with antibiotics or germ-free mice and increase the number of these cells in specific pathogen-free mice(37). These effects are caused partly by SCFA receptors, free fatty acid receptor 2 (known as GPR43), which is expressed at high levels by colonic Treg cells, but not in circulating Treg cells(38).

Recent findings have shown that metabolic status of the host and multiple metabolites of nutrients can affect hemostasis. Vitamins are essential organic compounds that are synthesized in the body or obtained from dietary sources(39). A variety of immunological disorders can occur as a result of vitamin deficiency(40). Vitamin A as one of the most important factors can regulate the intestinal immune cell function(41). Vitamin A is metabolized to RA in the intestine, which has pleiotropic effects on intestinal immune cells and regulates lymphocyte homing to the gut, intestinal IgA production, development of specific DC subsets, and Foxp3⁺ Treg cell differentiation(42-44). The extent of intestinal immune cell functions affected by RA suggests that vitamin A metabolism is important for immune homeostasis. In fact, the disruption of RA signaling leads to reduced intestinal Foxp3⁺ pTreg cell development in vivo(45), and vitamin A deficiency is associated with the induction of colitis(46). Also, vitamin D is a precursor of calcitriol (1, 25 dihydroxy-vitamin D), which maintains calcium and phosphate balance, regulates bone formation, and it has been proved to increase Treg cell differentiation and suppress immune responses(47). In the gut, vitamin D and

vitamin D receptor signaling contributes to improve chronic colitis in mouse models(48). In IBD, low level of vitamin D is reported that associated with higher severity of disease (49, 50). Therefore, vitamin A and D additives may have therapeutic effects in IBD disease via induction of intestinal Treg cells.

Treg function in the gut:

It has been well demonstrated that Treg cells play an important role in the regulation of intestinal immune responses to ensure the protection of host against pathogenic microorganisms and the lack of immune-related pathologies. In the lamina propria of the gut, Treg cells maintain intestinal homeostasis through negative regulation of effector T cells and play a pivotal role in intestinal inflammation suppression by production of IL-10 and TGF- β as well as increased expression of CTLA4(51). Earlier studies have highlighted an immunoregulatory role of IL-10 by showing that the use of antibodies against the receptor IL-10 or transfer of CD4⁺ T cells deficient in IL-10 to Rag1^{-/-} mice caused acute colitis (52, 53). Subsequent studies by searching for the mechanism of IL-10 regulatory activity in the transfer colitis model indicated that FOXP3⁺ cells deficient in the IL-10 receptor subunit β (IL-10R β) unable to protect recipient mice from colitis and missed their ability to express FOXP3, showing that IL-10R signaling in regulatory cells is significant to maintain of their function(54). The role of IL-10 in regulatory T cell function does not reject a role of TGF- β . The role of TGF- β in studies showing that protection from colitis by Treg cells when CD4⁺ CD25⁺ cells with defects in TGF- β into recipient mice were transplanted, did not occur and by the observation that systemic use of anti-TGF- β antibody blocked the ability of CD4⁺CD25⁺ T cells to attenuate colitis(55, 56). Also, TGF- β expressed on the surface of CD4⁺CD25⁺ T cells in relationship with LAP mediated CD4⁺CD25⁺ T cell suppression in vitro and CD4⁺LAP⁺, but not CD4⁺LAP⁻; T cells protected recipient mice from colitis(57).

IL-35 is an immunoregulatory cytokine that is secreted together with IL-10, TGF- β by FOXP3 Treg cells; especially in the presence of effector T cells, IL-35 is produced in considerable level whereby effector T cell proliferation is suppressed. Overexpression of IL-35 has been linked with increased induction of gastrointestinal cancers (58-60). These findings suggest that IL-35 plays a role in suppressing immunity against tumors.

Treg in Chronic intestinal inflammation: IBD and GI tumors

Tregs in IBD

Inflammatory bowel disease (IBD) is chronic autoimmune disorder that can involve the small intestine or colon, and basically consists of two types of ulcerative colitis (UC) and Crohn's disease (CD). Colorectal cancer risk is increased in patients with IBD. It is believed that IBD arise from a complex interaction of environmental factors, genetic

susceptibility, impaired epithelial defense barrier and lack of regulation of intestinal immune system(61). Although the exact mechanism involved is not yet clear, in recent years significant progress has been achieved in understanding the immunopathogenesis of IBD, resulting in new therapeutic and targeted strategies.

IBD mouse models that mimic features of human pathology have been helpful in better understanding and explaining the immunopathology of IBD. They show that chronic inflammation may be result in excessive inflammatory responses or defects in negative regulatory routes(62). In colitis models (T cell transfer model and IL-10 knockout model), role of Treg cells and related cytokines has been shown in IBD(63). Patients with IBD have reduced Treg cells in the peripheral blood compared to healthy individuals and increased in inflamed intestinal mucosa. Disease severity has a different effect on the number of Treg cells in peripheral blood and mucosa (64, 65), or these cells have less ability to suppress proliferation of autologous T cell (66). There are documents that Treg cells of peripheral blood and gut of IBD patients are more susceptible to apoptosis compared to non-inflamed colon tissues, and a decrease in Treg cell apoptosis along with an increase in the number of these cells and reduction in disease activity can be observed in patients treated by anti-TNF (67). It can be said that there is no complete evidence that Treg cells are functional or not. In many studies, based on *in vitro* suppression assays, Treg cells in patients with IBD had functional roles and it was shown that Treg cells in both peripheral blood (68) and mucosa of patients with Crohn's disease and ulcerative colitis (69, 70). The reason for the creation of a deleterious immune response, despite the presence of functional Treg cells in inflamed mucosa, can be effector T cells resistance to immunosuppressive effects of TGF- β . The upregulation of Smad7 (an inhibitor of TGF- β signalling) in the intestinal mucosa of IBD patients show resistance of cells to inhibition of Treg cells (71).

However, other studies have reported different results, indicating that IBDs could be due to functional defects of Treg cells (66, 72). It is impossible to determine whether these defects are initially responsible for the disease development in those patients or is secondary to the excessive inflammation triggered by other mechanisms. In IBD patients study, deficient suppressive function of Treg due to mutation in the FOXP3 gene has been reported *in vitro*(72), showing that a Treg defect may be a key cofactor for disease development. Although the genetic defect of Treg cells may not happen in most cases as an underlying cause of IBD, Treg deficiency associated with other genetic or environmental factors may be involved in the development or severity of the disease.

According to the correlation between the gut commensal flora and Treg cells it seems that in

IBD patients treatment by specified commensal bacteria may help to accurate dysbiosis and rectify the development of Treg cells along inflammation of the intestine(73).

Increasing the number of peripheral blood T cells co-expressing FOXP3 and IL-17 is observed in patients with CD and UC (66). These FOXP3⁺ IL-17⁺ T cells express the transcription factor ROR γ t, showing an intermediate phenotype between the Th17 and Treg subsets. In a study, FOXP3⁺ IL-17⁺ T cells have been detected in the mucosa of patients with CD, but not in UC (74), whereas another study reported their presence in patients with UC (75). Significant reduction in the ability of Treg cells in suppressing autologous T cell proliferation was associated with increased IL-17⁺ T cells among FOXP3⁺ Treg cells, while other studies have concluded that mucosal FOXP3⁺ IL-17⁺ T cells have the suppressive ability in patients with UC. Interestingly, other studies examining the mucosal FOXP3⁺ IL-17⁺ T cells functional capacities showed that these cells increased production of inflammatory cytokines IL-6 and IL-1 by colonic tissue cultures in an IL-17-dependent pathway(75). Thus, the capacities of pro-inflammatory by Treg cells simultaneously with the loss of their suppressive activity may be involved in the uncontrolled inflammation *in vivo*. An important point for understanding Treg function in IBD pathogenesis is the lack of reliable markers for identifying Tregs. The classical CD25 and Foxp3 markers that are applied in many works could also be expressed by activated effector T cells. So to achieve certain results, review of the studies will be required to identify Treg using a more refined phenotype.

The role of inhibitory cytokines in IBD

TGF- β : TGF- β is a pleiotropic cytokine released by some different cells in the gut that have a significant tolerogenic effect by promoting regulatory T cell differentiation(76). TGF- β regulates epithelial cell migration and plays an important role in tissue remodeling in the gut(77). TGF- β 1 is produced in large quantities in the gut(78). The active form of TGF- β binding to its receptor activates Smad2/3 proteins, which in the formation of a complex with Smad4 and its inclusion into the nucleus acts as a transcription factor. Smad7 by competitive binding to the receptor for TGF- β inhibits the phosphorylation of Smad2/3 induced by TGF- β 1, which is considered as a negative regulator of the TGF- β signaling pathway(79). However, Smad7 can react with other intracellular proteins and control cellular function through TGF- β 1 independent pathways(80). TGF- β 1 is highly expressed in inflamed mucosa of patients with IBD, but it is unable to activate Smad-associated intracellular signaling and suppress inflammatory responses. It has been shown that IBD-related inflammation is along with increased levels of Smad7(71). So that the silencing of the Smad7 by specific antisense oligonucleotide

restores TGF- β 1 function and this inhibits inflammatory cytokine production, and improves colitis in mice (81).

IL-10: IL-10 is an anti-inflammatory cytokine, which is produced by immune and non-immune cells. Secretion of IL-10 is one of the key inhibitory mechanisms in Treg cells for creating tolerance to self and environmental antigens, particularly in the colon, lung and skin (82). The important role of IL-10 in intestinal homeostasis have been proved by the use of recombinant IL-10 or intestinal bacteria able to produce IL-10 can moderate intestinal inflammation in mice (83, 84). In an IBD mouse model, IL-10 secretion by Treg cells and other cells controls the activation of proinflammatory macrophages (85, 86). IL-10 can directly inhibit the Th1 and Th17 colitogenic T cells (87), and IL-10 signaling in Treg cells is interestingly essential for colitogenic Th17 control (88). Therefore, IL-10 has an important role for Treg activation and suppressive functions.

G. Sarabayrouse et al. in a recent study detected CD4⁺CD8^{αα} cells as new subsets of FOXP3⁻ T cells in the blood and human colonic lamina propria which have similar regulatory functions to FOXP3⁺ T cells and secrete IL-10. *F. prausnitzii* bacterium from species of Clostridium of the gut microbiota is the main inducers of Treg cells and, interestingly, the study also showed that the bacteria levels were lower in patients with IBD compared to healthy colon mucosa of patients with colon cancer; and as a result, CD4⁺CD8^{αα} cells are reduced in the gut and the blood of these patients (89).

IL-35: IL-35 is vital for Treg-mediated control of the inflammatory responses in the gut. In fact, in the T cell transfer model of colitis, mice receiving Treg cells from animals deficient in a subunit of the IL-35 receptor were less protected than those transferred with wild-type Treg cells (90). It has been suggested that IL-35 exerts its regulatory effects by inducing the conversion of conventional T cells to induced Treg cells. Indeed, CD4⁺ T cell activation by IL-35 and TCR signals creates stable iTreg population (3).

Treg cells as a therapeutic tool in the treatment of IBD

In IBD disease, some therapies which were not designed to specifically target Treg cells exert beneficial effects on the disease and a simultaneous impact on Treg cells (91, 92). For example, therapeutic response to anti-TNF resulted in a reduction Treg apoptosis in UC, enhance treg suppression (67, 93) and increase the levels of TGF- β and IL-10 in responder patients (94). Treg cells transfer can treat intestinal pathology of mice (95), and this raised the use of Treg cells as a therapeutic method for IBD disease. Currently, administration of Treg cells has been used in patients with Crohn's disease in phase I and IIa clinical trial. A reduction of CD disease activity was observed in 40% of the patients (96). Encouraging results of this study has led to the development of a larger, ongoing, placebo-

controlled clinical trial to assess the effects of Treg cell therapy in patients with Crohn's disease who are resistant to conventional treatments. In order to more effectively Treg cells infused in controlling inflammation in patients with IBD, considering the purity of the cells Treg, the ability of homing, antigenic specificity and survival of Treg cells is likely to be strong to develop therapeutic regime.

Treg in gastrointestinal tumors

Treg cells in gastric cancer (GC):

Gastric cancer is the third most common cause of cancer-related mortality in the world (97). Unhealthy diet, smoking and above all infection with the bacterium *Helicobacter pylori* are the main risk factors for Gastric cancer (98). Treg cells play important roles in tumor escape in gastric cancer (99, 100). In the study of patients with gastric cancer, increasing the number of Treg cells has been shown in tumor tissue and peripheral blood (101, 102). The reason for the increased Treg cells into tumor is not only an increase in called Treg cells, but is also induction of FOXP3 expression in tumor site by tumor factors (103). For example, in patients with gastric, colon and lung cancers, one of the mechanisms that induce expression of FOXP3, expression levels of cyclooxygenase 2 (COX-2) by tumor cells has been shown to be mediated production of prostaglandin E2 (PGE2) (104-106). CD4⁺ CD25⁺ T cells treated with PGE2 lead to FOXP3 expression and induction of suppressive function of these cells (107). About the prognostic effect of Treg cells in gastric cancer, several studies have reported conflicting results; some studies have shown that Treg cells are protective, whereas in some other studies, Treg cells in TIL or in the peripheral blood of patients with GC are able to suppress effector T cells because of promoting tumor growth (102, 108). Several studies have shown that FOXP3 is expressed in variant tumor cells (100, 109, 110). But the function of FOXP3, in tumor cells is diverse and controversial. Several studies represent that the FOXP3 gene functions as both a tumor suppressor gene for breast, prostate and non-small cell lung cancer and an oncogenic gene for gastric cancer and hepatocellular carcinoma (111-114).

Moreover, recent data show that Th17 cells might somehow contribute to GC pathogenesis. One gets the impression Th17 cells and Treg balance is important in determining the severity of gastritis caused by *H. pylori*. Both Th17 and Treg cells localize to mucosal surfaces through CCL20 signaling, CCL20-CCR6 axis is currently the subject of several studies in patients with IBD (115, 116). Increased expressions of CCL20 in the mucosa of IBD patients and protection from CCR6⁺ Treg cell-mediated colitis have been shown in the studies (117, 118). There is growing evidence that *H. pylori* infection is negatively associated with IBD (119, 120). Cook KW et al., reported that enhanced Treg cells in peripheral blood express CCR6, and increased

expression of Ligand CCR6 (CCL20) in gastric epithelial cells of patients with *H. pylori* infection(121).

Treg cells in pancreatic cancer (PC):

Pancreatic cancer is a devastating form of cancer with a poor prognosis and 5-year survival rate of less than 5%, and most patients develop symptoms of pancreatic cancer in an advanced phase of the disease (122). In animal models, infiltration of Treg cells into pancreatic tumor tissue has been shown even in the early stages of tumor progression and creation of localized immunosuppression (123). Immunohistochemical studies have shown the presence of FOXP3⁺ Treg cells in pancreatic tumor tissue and their relationship with poor clinical prognosis. Several studies have examined the frequency of Treg cells in peripheral blood of patients with pancreatic cancer (124-127). Some studies reported increased CD4⁺CD25⁺ Treg cells, and some other demonstrated no change in CD4⁺CD25⁺FOXP3⁺ Treg cells in the blood of patients with cancer than in healthy controls (127), it seems that this inconsistency in results can be attributed to the defined Treg cells.

More recently, studies have been done on the biology of pancreatic adenocarcinoma and importance of tumor microenvironment in responding to treatment. In fact, one of the histologic features of pancreatic cancer is the dominant desmoplastic reaction, which in addition to pancreatic cancer cells (PCCs), pancreatic stellate cells (PSCs) are present in it. A study shows deleterious effects of PSC cells, which promote immunosuppression in tumor environment through the production of chemokine IP-10, and recruitment of CXCR3⁺ Treg cells (128); whereas, another study indicates that the PSC fibrosis can inhibit calling Treg cells into pancreatic tumor environment (129). However, in order to find an appropriate treatment strategy to improve the treatment of patients with pancreatic cancer, more clinical and basic researches are required to clarify the interaction between the immune system and PSC cells in these patients.

Treg cells in hepatocellular carcinoma (HCC):

Primary liver cancers include cholangiocarcinomas, hepatoblastomas and hepatocellular carcinomas, which the last type is the most common cancer with a high mortality rate and poor prognosis (130, 131). Evidence suggests that Treg cells are essential factors in the development and prognosis of HCC(132, 133). The available evidence shows that the HCC tumor cells can directly alter the liver microenvironment by Treg cells recruitment (134, 135), or induce Treg cells through TGF-β1 production (136) or up regulation the PD-1 (137), which have been associated with poor patient outcome and recurrence after surgery (138, 139). Increased repressive function and also abnormal functional phenotypes of Treg cells have been reported in patients with HCC. Treg cells in

peripheral blood of HCC patients up-regulate CCR6 receptor, which facilitates their migration into the tumor sites (134, 140, 141).

In a study on animal models and patients with HCC, it was found that the Treg cells in HCC had the specifically altered expression of miRNAs affected by FOXP3, which would target important signaling pathways that could affect the functions of Tregs(142).

Treg cells in CRC cancer:

Tumorigenesis in the colon is a complex and multi-step process, which is affected by external and internal factors, such as age, sex, diet, and other lifestyle-related diseases. The disease first appears as an adenomatous polyp, and then resulting in advanced adenoma with severe dysplasia, and eventually leads to invasive cancer. The immune system status in tumor microenvironment is involved on survival of patients with CRC(143). The failure to an effective immune response is thought to be because the tumor microenvironment dominated by immunosuppressive cells and in the meantime Treg cells have attracted special attention because of their ability to inhibit effector T cells, and increase the number of Treg cells enables tumor cells to evade the host immune response(144, 145).

For CRC patients, high number of Treg cells had been indicated in peripheral blood, tumor-draining lymph node, and tumor site (146, 147). On the other hand, since in patients with CRC, carcinoembryonic antigen (CEA), telomerase, HER2/neu, and MUC-1 reactive Treg cells were detected, these Treg cells are specific TAA reactive. Indeed, TAA-specific Treg cells predominantly are in the blood of CRC patients, but are not detectable in healthy subjects (148).

FOXP3⁺ Treg cells suppress tumor antigen-specific immune responses in CRC, which may explain ineffective immune response against the tumor (149). Results of a study show that Treg cells may impact on effector T cell trafficking into tumors. Treg-derived adenosine contributes to suppress transendothelial migration of effector T cells into tumors by reducing the ability of monocytes and ICAM to activate the endothelium in tumor patients. This effect of Treg cells is specifically for cancer patients (150).

Many studies indicate a various importance of Treg cells in CRC cancer. A research showed that in CRC intratumoral Treg cells suppressed matrix metalloproteases in the presence of IL-17, which were linked to decreased metastases (151). In another work, it was proved that in CRCs with high level of microsatellite instability (MSI-H), the density of FOXP3⁺ Treg cells infiltrating CRCs was significantly higher in parallel with enhanced number of CD8⁺ T cells and was along with good prognosis (152). Indeed, CRC models show that, at least in early-stages, CRC is along with prolonged pro-inflammatory damages resulting from gastrointestinal bacteria, and Treg cells are tool in

removing the local inflammation that this useful effect of Treg cells gets lost later by converting to a pathogenic phenotype(154).The prognostic effect of Treg in CRCs is controversial. A report indicated that increased peritumoral numbers of FOXP3⁺Treg cells are due to advanced-stage tumors and weaker overall survival (155). But, the improved survival by increasing the numbers of intratumoral FOXP3⁺ Treg cells has also been reported in CRC patients(146).

Heterogeneous nature of human intestinal tumor microenvironment may be involved in these paradoxical roles of Treg cells (146, 156).Treg cells subset that develop in human colorectal cancer differ in their ability to suppress inflammation in comparison to Treg cells which are abundant in healthy individuals. Blatner et al., in 2012reported a subset of Treg cells in human and mice modeling of colorectal cancer, which express FOXP3 and ROR γ t markers, and these cells have both pro-inflammatory and cell suppressive functions (157).Therefore, these findings suggest that Treg cells are usually very protective by suppressing inflammation in cancer, but changes of these cells to the cells expressing ROR γ t is deleterious. On the other hand, it has been shown that the activation of Wnt/ β -catenin signaling pathway increases ROR γ t expression in these T cells (158, 159).Thus, the activation of Wnt signaling pathway in inflammation conditions can inhibit the function of Treg cells, which the lack of control in this process can lead to autoimmune responses and even cancer.

The role of inhibitory cytokines in CRC

IL10 is an immunosuppressive cytokine that is upregulated in cancer, and it has been attributed with a role in inhibiting tumor lysis and tumor rejection as well as according some studies has a protective role.The immunosuppressive function of IL10 can be related to its effects on antigen-presenting cells and T cells. IL10 downregulates expression of costimulatory molecules by dendritic cells and induces T-cell anergy in dealing with the antigen (160, 161).The inhibitory impacts of IL10 are not always consistent; for instance IL10 in mice suppresses the proliferation of CD4⁺ T cells but not necessarily expression of cytokines such as IFN γ ; or IL10 has various effects on CD8⁺ T cellsand unexpectedly activates and expands tumor-resident T cells(162, 163). Inhibitory and enhancing effects of IL-10 on T cells depend on the activation status of these cells.The timing of exposure to IL10 seems to be significant, so that inhibitory effects at antigen priming, and stimulatory at recall(164).Recent results show important role of IL10 in IFN- γ - dependent tumor lysis and cytotoxic T-cell differentiation (163, 165, 166).The anti-inflammatory features of IL10, especially in the colon, indicate that this cytokine can suppress some immune responses while enhancing others.

In adenomatous polyps in the small intestine of APC ^{Δ 468} mouse model, deficient in IL-10 exacerbate the polyps in the colon and vice versa reduced in the

small intestine, suggesting different nature of inflammation in the small intestine and colon.Since polyps is inhibited in the colon but not in small intestine of germ-free mice or treated with antibiotics, this difference could be related to microbes (167, 168).

IL-10 production by Treg cells is essential to control tumorigenesis in intestinal dysplasia derived from inflammation(169).Similarly, in murine model of IBD showed that recombinant IL-10 can improve symptoms (170).However, clinical results in patients with IBD have been disappointing due to dose-limiting systemic toxicity of cytokine. Recently study on the APC^{min/+} mouse model of intestinal polyposis showed that oral administration of IL-10 by effects on IL-17-producing CD4⁺Foxp3⁺ROR γ t⁺ pathogenic T-regulatory can suppress polyps and improve systemic pathologies and increase the lifespan of mice(171).

TGF- β : TGF- β plays a dual role in human diseases with the influence of context. TGF- β can act as a tumor suppressor and oncogenes (172).Its tumor suppression functions, which are observed in the early stages of cancer and in normal cells, include inhibition of cell proliferation, induction of apoptosis and autophagy regulation. As tumors grow, they alter their response to TGF- β and this factor can be used as a strong promoter of cell motility, invasion, and metastasis as well as maintain tumor stem cell. Also, TGF- β induces epithelial to mesenchymal transition (EMT) in aggressive and invasive tumors (173). Studies have shown that TGF- β can activate the Smad-independent pathways. TGF- β induces activation of Erk signaling in colorectal cancer and breast cancer cells to promote of adherens junctions and cell migration (174, 175). It has been widely proven that increased expression of TGF- β , mutations or loss of TGF- β receptors or Smad2/4 could lead to the development of colorectal, pancreatic, gastric and prostate tumors (176).Allelic variants of Smad7 (TGF β signaling pathway inhibitor),characterized by reduced expression of Smad7, is associated with increased risk of colitis-associated colorectal cancer (177, 178).

In a mouse model, inducing increased Smad7expression in T cells was shown to promote the number of cells CD4⁺ T-bet⁺ ROR γ t⁺ T cells infiltration of tumor, which these cells produce TNF- α and IFN- γ ; in indeed, the plastic effects of Smad7 on T cells phenotype lead to protection against colon cancer (179).

IL-35:Immunosuppressive and anti-inflammatory functions of IL-35suppress T CD4 and T CD8 proliferation, as well as inhibit the TH17 function and cell differentiation into TH17 (3).Also, IL-35 possesses the ability to inhibit antibody response and plays a role in infectious tolerance (180, 181). Generally, IL-35 expression has been considered by suppressing immune system associated with tumor progression and poor prognosis(59, 182, 183). In a

study, increased expression of IL-35 in colorectal tumor cells and its relationship with tumor metastasis and clinical stages of the disease have been reported (60). However, conflicting results have been reported, for example, ectopic expression of IL-35 is said to suppress cell growth in cancer cells through G1 phase cell cycle arrest with increased apoptosis (184). But the exact impact of IL-35 is still not entirely clear on tumorigenesis, especially in the development and metastasis of colorectal cancer.

Treg cells as a therapeutic tool in the treatment of CRC

Treg cell-mediated immune suppression is one of the main barriers to succeeded tumor immunotherapy (185). Treg cells may be an attractive therapeutic target. Depletion of Tregs by cytotoxic drugs and Treg modulation in patients with CRC might raise antitumor immune immunotherapy (186). In addition, the study showed that depletion of Treg cells in the peripheral blood of patients with CRC enhances CD4⁺ T cell responses to TAA antigens (148). However, currently losses or profits of increased Treg cells are more controversial in CRC. Since there are differences between Treg cells and Effector T cells in the repertoires of TAA antigens recognized by these cells, selected sets of TAAs can be used for tumor vaccinations that induce optimal effector T-cell responses but at least Treg activity without the need for remove of Treg cells (187).

One of the new therapeutic approaches for cancer treatment is the immune checkpoint inhibitors. Preliminary studies suggest that the immune checkpoint inhibitors, especially anti-CTLA4, anti-PD-1 and anti-PD-L1 may be effective in the treatment of patients with gastrointestinal cancer (188-190). In advanced gastric and colonic cancer, different clinical trials using antibodies to CTLA4, PD-1 and PD-L1 alone or in combination are currently ongoing. Primary findings were elevated immune response by these drugs, while CTLA4 antibodies can increase T cells activated through APC cells in the lymphoid tissues, regulation of signaling pathways associated with PD-1 can lead to more effective function of effector T cells by interfering with tumor-associated immune suppression (188, 191, 192). Other immune checkpoints such as OX40, TIM 3 and LAG 3 are also in progress in early clinical trials (193-195). Therefore, combination therapies taking into account immune checkpoint inhibitors combined with other therapies such as chemotherapy, radiotherapy, etc. are suitable alternative treatment options, which are currently in early stages of development (196, 197). The combination of oncolytic virus with immune checkpoint inhibitors can increase the treatment efficiency of these inhibitors through induction of tumor infiltration (198, 199).

Concluding remarks

Regulatory T cells are a key factor in suppressing inflammation and maintaining immune tolerance, escaping tumor immune and reversing adoptive immunotherapy in cancer patients. The immunosuppressive function of Treg cells is especially important in the intestine where its mucosa is exposed to a variety of foreign antigens. Treg cell dysfunction is associated with a disruption in intestinal tolerance and imbalance of microbiota that may contribute to pathological inflammatory processes such as IBD and CRC diseases. Studies have reported Treg cells dysfunction in IBD patients and high densities of tumor-infiltrating Treg cells in CRC patients and its relationship with better or worse outcomes for disease. Detailed explanation is not clear for these inconsistent results. Treg cells phenotypic heterogeneity, gene expression and Treg cells functional activities may have contributed to the somewhat contradictory results; it can be noted to other factors such as insufficient markers or different techniques employed in researches to identify and monitor Treg cells, as well as microbial, nutritional and environmental agents associated with such diseases are important.

According to a heterogenous population of regulatory T cells, identifying the subsets of Treg cells and their specific roles is critical to the discovery of pathological Tregs, targeting them as opposed to systemic therapies and thus single cell analyses, such as single cell RNA-seq, may help to recognition these cells.

References

1. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. *Nature immunology*. 2005;6(4):353-60. Epub 2005/03/24.
2. Danese S, Rutella S. The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity. *Current medicinal chemistry*. 2007;14(6):649-66. Epub 2007/03/10.
3. Collison LW, Chaturvedi V, Henderson AL, Giacomini PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. *Nature immunology*. 2010;11(12):1093-101. Epub 2010/10/19.
4. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. *Blood*. 2005;105(3):1162-9. Epub 2004/10/14.
5. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. *Immunological reviews*. 2001;182:207-14. Epub 2001/11/28.
6. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. *Toxicologic pathology*. 2012;40(2):186-204. Epub 2012/01/10.
7. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. *Blood*. 2007;110(8):2983-90. Epub 2007/07/24.
8. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. *Immunology*. 2008;124(1):13-22. Epub 2008/03/19.
9. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. *Annual review of immunology*. 2012;30:733-58. Epub 2012/01/10.

10. Lowther DE, Hafler DA. Regulatory T cells in the central nervous system. *Immunological reviews*. 2012;248(1):156-69. Epub 2012/06/26.
11. Barnes MJ, Powrie F. Hybrid Treg cells: steel frames and plastic exteriors. *Nature immunology*. 2009;10(6):563-4. Epub 2009/05/19.
12. Sawant DV, Vignali DA. Once a Treg, always a Treg? *Immunological reviews*. 2014;259(1):173-91. Epub 2014/04/10.
13. Panduro M, Benoist C, Mathis D. Tissue Tregs. *Annual review of immunology*. 2016;34:609-33. Epub 2016/05/12.
14. Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. *Nature*. 2013;497(7448):258-62. Epub 2013/04/30.
15. Kuhn KA, Stappenbeck TS. Peripheral education of the immune system by the colonic microbiota. *Seminars in immunology*. 2013;25(5):364-9. Epub 2013/10/31.
16. Ai TL, Solomon BD, Hsieh CS. T-cell selection and intestinal homeostasis. *Immunological reviews*. 2014;259(1):60-74. Epub 2014/04/10.
17. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature*. 2013;500(7461):232-6. Epub 2013/07/12.
18. Iweala OI, Nagler CR. Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. *Immunological reviews*. 2006;213(3):82-100. Epub 2006/09/16.
19. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. *Science (New York, NY)*. 2011;331(6015):337-41. Epub 2011/01/06.
20. Kim KS, Hong SW, Han D, Yi J, Jung J, Yang BG, et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. *Science (New York, NY)*. 2016;351(6275):858-63. Epub 2016/01/30.
21. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. *Journal of immunology (Baltimore, Md : 1950)*. 2008;181(4):2277-84. Epub 2008/08/08.
22. Hammerschmidt SI, Friedrichsen M, Boelter J, Lyszkiewicz M, Kremmer E, Pabst O, et al. Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice. *The Journal of clinical investigation*. 2011;121(8):3051-61. Epub 2011/07/09.
23. Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. *Cell & bioscience*. 2011;1(1):20. Epub 2011/06/30.
24. Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille JJ, Curotto de Lafaille MA. Oral tolerance in the absence of naturally occurring Tregs. *The Journal of clinical investigation*. 2005;115(7):1923-33. Epub 2005/06/07.
25. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. *Nature*. 2012;482(7385):395-9. Epub 2012/02/10.
26. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. *Nature*. 2011;478(7368):250-4. Epub 2011/09/23.
27. Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. *Immunity*. 2011;35(1):109-22. Epub 2011/07/05.
28. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. *Journal of immunology (Baltimore, Md : 1950)*. 2010;184(7):3433-41. Epub 2010/02/26.
29. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. *Journal of immunology (Baltimore, Md : 1950)*. 2012;188(3):976-80. Epub 2011/12/27.
30. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. *Journal of immunology (Baltimore, Md : 1950)*. 2013;190(5):2001-8. Epub 2013/01/30.
31. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. *The Journal of experimental medicine*. 2012;209(10):1713-22. Epub 2012/09/12.
32. Milpied P, Renand A, Bruneau J, Mendes-da-Cruz DA, Jacquelin S, Asnafi V, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. *European journal of immunology*. 2009;39(6):1466-71. Epub 2009/06/06.
33. Kurashima Y, Goto Y, Kiyono H. Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation. *European journal of immunology*. 2013;43(12):3108-15. Epub 2014/01/15.
34. Farkas AM, Panea C, Goto Y, Nakato G, Galan-Diez M, Narushima S, et al. Induction of Th17 cells by segmented filamentous bacteria in the murine intestine. *Journal of immunological methods*. 2015;421:104-11. Epub 2015/04/11.
35. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(27):12204-9. Epub 2010/06/23.
36. Narushima S, Sugiura Y, Oshima K, Atarashi K, Hattori M, Suematsu M, et al. Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia. *Gut microbes*. 2014;5(3):333-9. Epub 2014/03/20.
37. Arpaia N, Campbell C, Fan X, Dikly S, van der Veecken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013;504(7480):451-5. Epub 2013/11/15.
38. Kim CH, Park J, Kim M. Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. *Immune network*. 2014;14(6):277-88. Epub 2015/01/01.
39. Veldhoen M, Ferreira C. Influence of nutrient-derived metabolites on lymphocyte immunity. *Nature medicine*. 2015;21(7):709-18. Epub 2015/06/30.
40. Masri OA, Chalhoub JM, Sharara AI. Role of vitamins in gastrointestinal diseases. *World journal of gastroenterology*. 2015;21(17):5191-209. Epub 2015/05/09.
41. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. *Nature reviews Immunology*. 2008;8(9):685-98. Epub 2009/01/28.
42. Benson MJ, Pino-Lagos K, Roseblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. *The Journal of experimental medicine*. 2007;204(8):1765-74. Epub 2007/07/11.
43. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. *The Journal of experimental medicine*. 2007;204(8):1775-85. Epub 2007/07/11.
44. Tokuyama H, Tokuyama Y. The regulatory effects of all-trans-retinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL-5 and inhibits IgG1 switching. *Cellular immunology*. 1999;192(1):41-7. Epub 1999/03/06.
45. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science (New York, NY)*. 2007;317(5835):256-60. Epub 2007/06/16.
46. Reifen R, Nur T, Ghebermeskel K, Zaiger G, Urizky R, Pines M. Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor-kappaB and collagen formation. *The Journal of nutrition*. 2002;132(9):2743-7. Epub 2002/09/11.
47. Mouli VP, Ananthkrishnan AN. Review article: vitamin D and inflammatory bowel diseases. *Alimentary pharmacology & therapeutics*. 2014;39(2):125-36. Epub 2013/11/19.
48. Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. *The Journal of clinical investigation*. 2013;123(9):3983-96. Epub 2013/08/16.
49. Ananthkrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, et al. Higher predicted vitamin D status is

- associated with reduced risk of Crohn's disease. *Gastroenterology*. 2012;142(3):482-9. Epub 2011/12/14.
50. Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. *Pharmacogenetics and genomics*. 2011;21(9):559-64. Epub 2011/08/13.
 51. Harrison OJ, Powrie FM. Regulatory T cells and immune tolerance in the intestine. *Cold Spring Harbor perspectives in biology*. 2013;5(7). Epub 2013/07/03.
 52. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. *The Journal of experimental medicine*. 1999;190(7):995-1004. Epub 1999/10/06.
 53. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, Muller W, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. *The Journal of experimental medicine*. 1996;184(1):241-51. Epub 1996/07/01.
 54. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. *Nature immunology*. 2009;10(11):1178-84. Epub 2009/09/29.
 55. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4+CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. *The Journal of experimental medicine*. 2001;194(5):629-44. Epub 2001/09/06.
 56. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. *The Journal of experimental medicine*. 1996;183(6):2669-74. Epub 1996/06/01.
 57. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. *Journal of immunology (Baltimore, Md : 1950)*. 2004;172(2):834-42. Epub 2004/01/07.
 58. Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH, et al. IL-35 over-expression is associated with genesis of gastric cancer. *Asian Pacific journal of cancer prevention : APJCP*. 2015;16(7):2845-9. Epub 2015/04/10.
 59. Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L, et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2015;36(4):2651-6. Epub 2014/12/07.
 60. Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. *International journal of clinical and experimental pathology*. 2013;6(9):1806-16. Epub 2013/09/17.
 61. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. *Lancet (London, England)*. 2007;369(9573):1627-40. Epub 2007/05/15.
 62. Uhlig HH, Powrie F. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. *European journal of immunology*. 2009;39(8):2021-6. Epub 2009/08/13.
 63. Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. *American journal of physiology Gastrointestinal and liver physiology*. 2009;296(2):G135-46. Epub 2008/11/27.
 64. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. *Journal of clinical immunology*. 2010;30(1):80-9. Epub 2009/11/26.
 65. Holmen L, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjoval H, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. *Inflammatory bowel diseases*. 2006;12(6):447-56. Epub 2006/06/16.
 66. Ueno A, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. *Inflammatory bowel diseases*. 2013;19(12):2522-34. Epub 2013/10/08.
 67. Veltkamp C, Anstaett M, Wahl K, Moller S, Gangl S, Bachmann O, et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. *Gut*. 2011;60(10):1345-53. Epub 2011/04/05.
 68. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. *Gastroenterology*. 2005;128(7):1868-78. Epub 2005/06/09.
 69. Kelsen J, Agnholt J, Hoffmann HJ, Romer JL, Hvas CL, Dahlerup JF. FoxP3(+)/CD4(+)/CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. *Clinical and experimental immunology*. 2005;141(3):549-57. Epub 2005/07/28.
 70. Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. *Clinical immunology (Orlando, Fla)*. 2007;125(3):281-90. Epub 2007/09/28.
 71. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. *The Journal of clinical investigation*. 2001;108(4):601-9. Epub 2001/08/24.
 72. Okou DT, Mondal K, Faubion WA, Kobrynski LJ, Denson LA, Mulle JG, et al. Exome sequencing identifies a novel FOXP3 mutation in a 2-generation family with inflammatory bowel disease. *Journal of pediatric gastroenterology and nutrition*. 2014;58(5):561-8. Epub 2014/05/06.
 73. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(5):2159-64. Epub 2010/01/19.
 74. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. *Gastroenterology*. 2011;140(3):957-65. Epub 2010/12/15.
 75. Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. *Journal of immunology (Baltimore, Md : 1950)*. 2011;186(7):4388-95. Epub 2011/03/02.
 76. Biancheri P, Giuffrida P, Docena GH, MacDonald TT, Corazza GR, Di Sabatino A. The role of transforming growth factor (TGF)-beta in modulating the immune response and fibrogenesis in the gut. *Cytokine & growth factor reviews*. 2014;25(1):45-55. Epub 2013/12/18.
 77. Ciacci C, Lind SE, Podolsky DK. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. *Gastroenterology*. 1993;105(1):93-101. Epub 1993/07/01.
 78. Faria AM, Weiner HL. Oral tolerance and TGF-beta-producing cells. *Inflammation & allergy drug targets*. 2006;5(3):179-90. Epub 2006/08/22.
 79. Massague J, Chen YG. Controlling TGF-beta signaling. *Genes & development*. 2000;14(6):627-44. Epub 2000/03/25.
 80. Briones-Orta MA, Tecalco-Cruz AC, Sosa-Garrocho M, Caligaris C, Macias-Silva M. Inhibitory Smad7: emerging roles in health and disease. *Current molecular pharmacology*. 2011;4(2):141-53. Epub 2011/01/13.
 81. Zorzi F, Angelucci E, Sedda S, Pallone F, Monteleone G. Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2013;45(7):552-5. Epub 2013/01/05.
 82. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity*. 2008;28(4):546-58. Epub 2008/04/05.
 83. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. *Immunity*. 1994;1(7):553-62. Epub 1994/10/01.

84. Steidler L, Hans W, Schotte L, Neiryck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. *Science* (New York, NY). 2000;289(5483):1352-5. Epub 2000/08/26.
85. Shouval DS, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. *Immunity*. 2014;40(5):706-19. Epub 2014/05/06.
86. Zigmund E, Bernshtein B, Friedlander G, Walker CR, Yona S, Kim KW, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. *Immunity*. 2014;40(5):720-33. Epub 2014/05/06.
87. Huber S, Gagliani N, Esplugues E, O'Connor W, Jr., Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. *Immunity*. 2011;34(4):554-65. Epub 2011/04/23.
88. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. *Immunity*. 2011;34(4):566-78. Epub 2011/04/23.
89. Sarabayrouse G, Bossard C, Chauvin JM, Jarry A, Meurette G, Quevrain E, et al. CD4CD8 α phaalpha lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. *PLoS biology*. 2014;12(4):e1001833. Epub 2014/04/10.
90. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature*. 2007;450(7169):566-9. Epub 2007/11/23.
91. Dige A, Hvas CL, Deleuran B, Kelsen J, Bendix-Struve M, Dahlerup JF, et al. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells. *Scandinavian journal of gastroenterology*. 2011;46(10):1206-14. Epub 2011/07/29.
92. Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, et al. Demonstration of low-regulatory CD25^{High}+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. *Digestive diseases and sciences*. 2007;52(10):2725-31. Epub 2007/04/04.
93. Boschetti G, Nancey S, Sardi F, Roblin X, Flourie B, Kaiserlian D. Therapy with anti-TNF α antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. *Inflammatory bowel diseases*. 2011;17(1):160-70. Epub 2010/09/18.
94. Di Sabatino A, Biancheri P, Piconese S, Rosado MM, Ardizzone S, Rovedatti L, et al. Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn's disease. *Inflammatory bowel diseases*. 2010;16(11):1891-7. Epub 2010/09/18.
95. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. *Journal of immunology* (Baltimore, Md : 1950). 2003;170(8):3939-43. Epub 2003/04/12.
96. Desreumaux P, Foussat A, Allez M, Beauverger L, Hebuterne X, Bouhnik Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. *Gastroenterology*. 2012;143(5):1207-17 e1-2. Epub 2012/08/14.
97. Lindsey A, Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jema. *Global Cancer Statistics, 2012*. CA CANCER J CLIN 2015;65:87-108.
98. Brenner H, Rothenbacher D, Arndt V. *Epidemiology of stomach cancer*. *Methods in molecular biology* (Clifton, NJ). 2009;472:467-77. Epub 2008/12/25.
99. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. *Clinical immunology* (Orlando, Fla). 2009;131(1):109-18. Epub 2009/01/21.
100. Yuan XL, Chen L, Li MX, Dong P, Xue J, Wang J, et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. *Clinical immunology* (Orlando, Fla). 2010;134(3):277-88. Epub 2009/11/11.
101. Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding-Jarbrink M. CD4+ CD25^{high} regulatory T cells reduce T cell transendothelial migration in cancer patients. *European journal of immunology*. 2007;37(1):282-91. Epub 2006/12/14.
102. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2003;9(12):4404-8. Epub 2003/10/14.
103. Mizukami Y, Kono K, Kawaguchi Y, Akaie H, Kamimura K, Sugai H, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. *International journal of cancer*. 2008;122(10):2286-93. Epub 2008/01/29.
104. Bartchewsky W, Jr., Martini MR, Masiero M, Squassoni AC, Alvarez MC, Ladeira MS, et al. Effect of Helicobacter pylori infection on IL-8, IL-1 β and COX-2 expression in patients with chronic gastritis and gastric cancer. *Scandinavian journal of gastroenterology*. 2009;44(2):153-61. Epub 2008/11/06.
105. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. *Cancer research*. 2005;65(12):5211-20. Epub 2005/06/17.
106. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjornbeth BA, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. *Cancer immunology, immunotherapy : CII*. 2008;57(6):813-21. Epub 2007/10/27.
107. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. *Journal of immunology* (Baltimore, Md : 1950). 2005;175(3):1483-90. Epub 2005/07/22.
108. Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C, et al. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. *Journal of cancer research and clinical oncology*. 2010;136(10):1585-95. Epub 2010/03/12.
109. Won KY, Kim HS, Sung JY, Kim GY, Lee J, Park YK, et al. Tumoral FOXP3 has potential oncogenic function in conjunction with the p53 tumor suppressor protein and infiltrated Tregs in human breast carcinomas. *Pathology, research and practice*. 2013;209(12):767-73. Epub 2013/09/28.
110. Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. *The Journal of clinical investigation*. 2007;117(12):3765-73. Epub 2007/11/17.
111. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. *Lung cancer* (Amsterdam, Netherlands). 2012;75(1):95-101. Epub 2011/07/02.
112. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. *Cancer cell*. 2009;16(4):336-46. Epub 2009/10/06.
113. Wang WH, Jiang CL, Yan W, Zhang YH, Yang JT, Zhang C, et al. FOXP3 expression and clinical characteristics of hepatocellular carcinoma. *World journal of gastroenterology*. 2010;16(43):5502-9. Epub 2010/11/19.
114. Yoshii M, Tanaka H, Ohira M, Mugeruma K, Iwauchi T, Lee T, et al. Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. *British journal of cancer*. 2012;106(10):1668-74. Epub 2012/05/10.
115. Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, et al. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. *BioEssays : news and reviews in molecular, cellular and developmental biology*. 2010;32(12):1067-76. Epub 2010/10/19.
116. Lee AY, Eri R, Lyons AB, Grimm MC, Korner H. CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil? *Frontiers in immunology*. 2013;4:194. Epub 2013/07/23.

- 117.Kaser A, Ludwiczek O, Holzmann S, Moschen AR, Weiss G, Enrich B, et al. Increased expression of CCL20 in human inflammatory bowel disease. *Journal of clinical immunology*. 2004;24(1):74-85. Epub 2004/03/05.
- 118.Kitamura K, Farber JM, Kelsall BL. CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. *Journal of immunology* (Baltimore, Md : 1950). 2010;185(6):3295-304. Epub 2010/08/20.
- 119.Luther J, Dave M, Higgins PD, Kao JY. Association between *Helicobacter pylori* infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. *Inflammatory bowel diseases*. 2010;16(6):1077-84. Epub 2009/09/18.
- 120.Sonnenberg A, Genta RM. Low prevalence of *Helicobacter pylori* infection among patients with inflammatory bowel disease. *Alimentary pharmacology & therapeutics*. 2012;35(4):469-76. Epub 2012/01/10.
- 121.Cook KW, Letley DP, Ingram RJ, Staples E, Skjoldmose H, Atherton JC, et al. CCL20/CCR6-mediated migration of regulatory T cells to the *Helicobacter pylori*-infected human gastric mucosa. *Gut*. 2014;63(10):1550-9. Epub 2014/01/18.
- 122.Kelsen DP, Portenoy R, Thaler H, Tao Y, Brennan M. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. *Surgery*. 1997;122(1):53-9. Epub 1997/07/01.
- 123.Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. *Cancer research*. 2007;67(19):9518-27. Epub 2007/10/03.
- 124.Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2006;12(18):5423-34. Epub 2006/09/27.
- 125.Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. *British journal of cancer*. 2013;108(4):914-23. Epub 2013/02/07.
- 126.Vizio B, Novarino A, Giacobino A, Cristiano C, Prati A, Ciuffreda L, et al. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. *Experimental and therapeutic medicine*. 2012;4(1):70-8. Epub 2012/10/13.
- 127.Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Hirooka S, Yamaki S, et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. *Pancreas*. 2012;41(3):409-15. Epub 2011/12/14.
- 128.Lunardi S, Jamieson NB, Lim SY, Griffiths KL, Carvalho-Gaspar M, Al-Assar O, et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. *Oncotarget*. 2014;5(22):11064-80. Epub 2014/11/22.
- 129.Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer cell*. 2014;25(6):719-34. Epub 2014/05/27.
- 130.Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. *Annals of the New York Academy of Sciences*. 2002;963:13-20. Epub 2002/07/04.
- 131.Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin*. 2005;55(2):74-108. Epub 2005/03/12.
- 132.Wang HY, Wang RF. Regulatory T cells and cancer. *Current opinion in immunology*. 2007;19(2):217-23. Epub 2007/02/20.
- 133.Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. *International journal of cancer*. 2009;125(7):1640-8. Epub 2009/07/02.
- 134.Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. *PLoS one*. 2011;6(9):e24671. Epub 2011/09/22.
- 135.Yang J, Zhang JX, Wang H, Wang GL, Hu QG, Zheng QC. Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. *World journal of gastroenterology*. 2012;18(23):2938-47. Epub 2012/06/28.
- 136.Wang Y, Liu T, Tang W, Deng B, Chen Y, Zhu J, et al. Hepatocellular Carcinoma Cells Induce Regulatory T Cells and Lead to Poor Prognosis via Production of Transforming Growth Factor-beta1. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2016;38(1):306-18. Epub 2016/01/23.
- 137.Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2009;15(3):971-9. Epub 2009/02/04.
- 138.Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. *International journal of cancer*. 2011;128(4):887-96. Epub 2010/05/18.
- 139.Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, et al. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. *International journal of clinical oncology*. 2010;15(6):552-8. Epub 2010/10/22.
- 140.Cabrera R, Ararat M, Eksioğlu EA, Cao M, Xu Y, Wasserfall C, et al. Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma. *Scandinavian journal of immunology*. 2010;72(4):293-301. Epub 2010/10/05.
- 141.Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)/CD25(+) regulatory T cells. *Laboratory investigation; a journal of technical methods and pathology*. 2007;87(6):582-90. Epub 2007/03/21.
- 142.Chen L, Ma H, Hu H, Gao L, Wang X, Ma J, et al. Special role of Foxp3 for the specifically altered microRNAs in Regulatory T cells of HCC patients. *BMC cancer*. 2014;14:489. Epub 2014/07/09.
- 143.Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. *Clinical colorectal cancer*. 2016. Epub 2016/03/12.
- 144.Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: Current controversies and future perspectives. *European journal of immunology*. 2006;36(11):2832-6. Epub 2006/10/20.
- 145.Medina-Echeverez J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. *Journal of immunology* (Baltimore, Md : 1950). 2011;186(2):807-15. Epub 2010/12/15.
- 146.Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, et al. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. *Gut*. 2012;61(8):1163-71. Epub 2011/12/31.
- 147.Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. *Cancer research*. 2012;72(5):1092-102. Epub 2012/01/28.
- 148.Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. *The Journal of clinical investigation*. 2009;119(11):3311-21. Epub 2009/10/08.
- 149.Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. *PLoS one*. 2006;1:e129. Epub 2007/01/06.
- 150.Sundstrom P, Stenstad H, Langenes V, Ahlmanner F, Theander L, Ndah TG, et al. Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism. *Cancer immunology research*. 2016;4(3):183-93. Epub 2016/01/21.
- 151.Wang Q, Feng M, Yu T, Liu X, Zhang P. Intratumoral regulatory T cells are associated with suppression of colorectal carcinoma metastasis after resection through overcoming IL-17 producing

- T cells. *Cellular immunology*. 2014;287(2):100-5. Epub 2014/02/04.
152. Michel S, Benner A, Tariverdian M, Wentzensen N, Hoefler P, Pommerenke T, et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. *British journal of cancer*. 2008;99(11):1867-73. Epub 2008/11/06.
 153. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2012;18(11):3022-9. Epub 2012/04/19.
 154. Zhang X, Kelaria S, Kerstetter J, Wang J. The functional and prognostic implications of regulatory T cells in colorectal carcinoma. *Journal of gastrointestinal oncology*. 2015;6(3):307-13. Epub 2015/06/02.
 155. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. *Cancer research*. 2013;73(2):539-49. Epub 2012/10/31.
 156. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. *Gut*. 2008;57(6):772-9. Epub 2007/10/30.
 157. Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, Phillips JD, et al. Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. *Science translational medicine*. 2012;4(164):164ra59. Epub 2012/12/18.
 158. Keerthivasan S, Aghajani K, Dose M, Molinero L, Khan MW, Venkateswaran V, et al. beta-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. *Science translational medicine*. 2014;6(225):225ra28. Epub 2014/02/28.
 159. Shi J, Chi S, Xue J, Yang J, Li F, Liu X. Emerging Role and Therapeutic Implication of Wnt Signaling Pathways in Autoimmune Diseases. *Journal of immunology research*. 2016;2016:9392132. Epub 2016/04/26.
 160. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. *Blood*. 1999;93(5):1634-42. Epub 1999/02/25.
 161. Steinbrink K, Wolf M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. *Journal of immunology (Baltimore, Md : 1950)*. 1997;159(10):4772-80. Epub 1997/11/20.
 162. de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. *Journal of immunology (Baltimore, Md : 1950)*. 1993;150(11):4754-65. Epub 1993/06/01.
 163. Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, et al. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. *Cancer research*. 2012;72(14):3570-81. Epub 2012/05/15.
 164. Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. *Blood*. 2001;98(7):2143-51. Epub 2001/09/25.
 165. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFN-gamma-dependent tumor immune surveillance. *Cancer cell*. 2011;20(6):781-96. Epub 2011/12/17.
 166. Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-gamma-mediated CD8(+) T cell cytotoxicity. *BioEssays : news and reviews in molecular, cellular and developmental biology*. 2013;35(7):623-31. Epub 2013/05/15.
 167. Dennis KL, Wang Y, Blatner NR, Wang S, Saadalla A, Trudeau E, et al. Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. *Cancer research*. 2013;73(19):5905-13. Epub 2013/08/21.
 168. Gounaris E, Tung CH, Restaino C, Maehr R, Kohler R, Joyce JA, et al. Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. *PloS one*. 2008;3(8):e2916. Epub 2008/08/14.
 169. Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of interleukin-10 and regulatory T-cells in cancer. *Current opinion in oncology*. 2013;25(6):637-45. Epub 2013/10/01.
 170. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. *Immunological reviews*. 2008;223:114-31. Epub 2008/07/11.
 171. Ozbilge H, LeVea C, Chung AY, Li Q, Egilmez NK. Modulating gut immunity and neoplasia with oral cytokine adjuvants. *Oncoimmunology*. 2015;4(4):e1002724. Epub 2015/07/03.
 172. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. *Trends in biochemical sciences*. 2004;29(5):265-73. Epub 2004/05/08.
 173. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. *Cell research*. 2009;19(2):156-72. Epub 2009/01/21.
 174. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. *Neoplasia (New York, NY)*. 2004;6(5):603-10. Epub 2004/11/19.
 175. Zhang YE. Non-Smad pathways in TGF-beta signaling. *Cell research*. 2009;19(1):128-39. Epub 2008/12/31.
 176. Massagué J. TGFβ in Cancer. *Cell*. 2008;134(2):215-30.
 177. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. *Nature genetics*. 2007;39(11):1315-7. Epub 2007/10/16.
 178. Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, van Wezel T, et al. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. *Genome research*. 2009;19(6):987-93. Epub 2009/04/28.
 179. Rizzo A, De Mare V, Rocchi C, Stolfi C, Colantoni A, Neurath MF, et al. Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. *Carcinogenesis*. 2014;35(7):1536-46. Epub 2014/02/01.
 180. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. *Journal of immunology (Baltimore, Md : 1950)*. 2010;184(12):7144-53. Epub 2010/05/21.
 181. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. *European journal of immunology*. 2007;37(11):3021-9. Epub 2007/09/18.
 182. Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. *Human immunology*. 2014;75(1):29-33. Epub 2013/10/15.
 183. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. *Journal of immunology (Baltimore, Md : 1950)*. 2013;190(5):2415-23. Epub 2013/01/25.
 184. Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. *Biochemical and biophysical research communications*. 2013;430(1):364-9. Epub 2012/11/17.
 185. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nature reviews Immunology*. 2006;6(4):295-307. Epub 2006/03/25.
 186. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. *Nature medicine*. 2011;17(9):1094-100. Epub 2011/08/30.
 187. Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines. *Current opinion in oncology*. 2009;21(6):524-30. Epub 2009/09/23.
 188. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. *The Annals of pharmacotherapy*. 2015;49(8):907-37. Epub 2015/05/21.
 189. Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. *Clinical cancer research : an*

- official journal of the American Association for Cancer Research. 2010;16(5):1662-72. Epub 2010/02/25.
190. Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune Therapy in GI Malignancies: A Review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2015;33(16):1745-53. Epub 2015/04/29.
191. Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. *Drug design, development and therapy*. 2015;9:901-9. Epub 2015/03/04.
192. Yuan J, Zhang J, Zhu Y, Li N, Tian T, Li Y, et al. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. *Oncotarget*. 2016. Epub 2016/05/19.
193. Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. *Cancer immunology research*. 2014;2(5):393-8. Epub 2014/05/06.
194. Curti BD, Kovacs-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. *Cancer research*. 2013;73(24):7189-98. Epub 2013/11/02.
195. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. *Nature reviews Immunology*. 2015;15(1):45-56. Epub 2014/12/24.
196. Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. *Seminars in oncology*. 2015;42(3):363-77. Epub 2015/05/13.
197. Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. *European journal of immunology*. 2015;45(7):1892-905. Epub 2015/05/29.
198. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. *Nature reviews Cancer*. 2014;14(8):559-67. Epub 2014/07/06.
199. Rojas JJ, Sampath P, Hou W, Thorne SH. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2015;21(24):5543-51. Epub 2015/07/19.